Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4,
programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment
of NSCLC, from back-line to first-line, and beyond. Is changing the standard of care for
NSCLC. Currently, several phases Ⅲ clinical studies of neoadjuvant immunity combined with
standard chemotherapy are underway, suggested that neoadjuvant ICI therapy is a promising way
for locally advanced lung cancer. As an intermediate state in the process of tumor
metastasis, Oligometastatic NSCLC patients have a better prognosis and more likely to benefit
from local treatment than patients with extensive distant metastasis. However, there have
been few reports of salvage surgery after ICI treatment in Oligometastatic NSCLC, and only
one case has been reported to date. There is therefore a need to further gather evidence on
salvage surgery after ICI.